Cannabis and cannabinoids for mental health indications: evidence of effect and adverse events

ABSTRACT: Cannabis and cannabinoids have been marketed and sold for a variety of different psychiatric conditions like e.g., anxiety, sleep problems, ADHD, PTSD, and even psychosis. Some of these indications may be reasonable, but for some a more conservative approach should be upheld. There are qui...

Descripción completa

Detalles Bibliográficos
Autor principal: Bramness, J. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417932/
http://dx.doi.org/10.1192/j.eurpsy.2023.101
_version_ 1785088156964487168
author Bramness, J. G.
author_facet Bramness, J. G.
author_sort Bramness, J. G.
collection PubMed
description ABSTRACT: Cannabis and cannabinoids have been marketed and sold for a variety of different psychiatric conditions like e.g., anxiety, sleep problems, ADHD, PTSD, and even psychosis. Some of these indications may be reasonable, but for some a more conservative approach should be upheld. There are quite a few open studies and case reports on effects, while larger blinded RCTs either fail to find these effects or are lacking. The lecture aims at presenting the most recent evidence for the use of cannabis and cannabinoids for psychiatric indications, alongside a presentation of adverse effects. DISCLOSURE OF INTEREST: None Declared
format Online
Article
Text
id pubmed-10417932
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-104179322023-08-12 Cannabis and cannabinoids for mental health indications: evidence of effect and adverse events Bramness, J. G. Eur Psychiatry Abstract ABSTRACT: Cannabis and cannabinoids have been marketed and sold for a variety of different psychiatric conditions like e.g., anxiety, sleep problems, ADHD, PTSD, and even psychosis. Some of these indications may be reasonable, but for some a more conservative approach should be upheld. There are quite a few open studies and case reports on effects, while larger blinded RCTs either fail to find these effects or are lacking. The lecture aims at presenting the most recent evidence for the use of cannabis and cannabinoids for psychiatric indications, alongside a presentation of adverse effects. DISCLOSURE OF INTEREST: None Declared Cambridge University Press 2023-07-19 /pmc/articles/PMC10417932/ http://dx.doi.org/10.1192/j.eurpsy.2023.101 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Bramness, J. G.
Cannabis and cannabinoids for mental health indications: evidence of effect and adverse events
title Cannabis and cannabinoids for mental health indications: evidence of effect and adverse events
title_full Cannabis and cannabinoids for mental health indications: evidence of effect and adverse events
title_fullStr Cannabis and cannabinoids for mental health indications: evidence of effect and adverse events
title_full_unstemmed Cannabis and cannabinoids for mental health indications: evidence of effect and adverse events
title_short Cannabis and cannabinoids for mental health indications: evidence of effect and adverse events
title_sort cannabis and cannabinoids for mental health indications: evidence of effect and adverse events
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417932/
http://dx.doi.org/10.1192/j.eurpsy.2023.101
work_keys_str_mv AT bramnessjg cannabisandcannabinoidsformentalhealthindicationsevidenceofeffectandadverseevents

Ejemplares similares